Dual Probes for Positron Emission Tomography (PET) and Fluorescence Imaging (FI) of Cancer

Richard Yuen; Frederick G West; Frank Wuest

doi:10.3390/pharmaceutics14030645

Dual Probes for Positron Emission Tomography (PET) and Fluorescence Imaging (FI) of Cancer

Pharmaceutics. 2022 Mar 15;14(3):645. doi: 10.3390/pharmaceutics14030645.

Authors

Richard Yuen¹, Frederick G West^{1

2}, Frank Wuest^{1

2

3}

Affiliations

¹ Department of Chemistry, University of Alberta, Edmonton, AB T6G 2G2, Canada.
² Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB T6G 2E1, Canada.
³ Department of Oncology, University of Alberta-Cross Cancer Institute, Edmonton, AB T6G IZ2, Canada.

Abstract

Dual probes that possess positron emission tomography (PET) and fluorescence imaging (FI) capabilities are precision medicine tools that can be used to improve patient care and outcomes. Detecting tumor lesions using PET, an extremely sensitive technique, coupled with fluorescence-guided surgical resection of said tumor lesions can maximize the removal of cancerous tissue. The development of novel molecular probes is important for targeting different biomarkers as every individual case of cancer has different characteristics. This short review will discuss some aspects of dual PET/FI probes and explore the recently reported examples.

Keywords: cancer imaging; dual probes; fluorescence; positron emission tomography.

Publication types

Review